The drug company Corbus Pharmaceuticals will start its next Phase 2 clinical trial to test a potential inflammation-targeting drug in people with cystic fibrosis in the first quarter of 2018.
Site Search
Showing 1 - 10 of 53 results
News
|
May 6, 2011
|
1 min read
News
|
Jan. 30, 2018
|
3 min read
Icagen Inc. will focus on drug discovery, screening for compounds that could suppress nonsense mutations, and using computer modeling to identify molecules that are suitable to be developed into drugs.
News
|
May 1, 2018
|
2 min read
News
|
Sept. 16, 2008
|
1 min read
News
|
March 11, 2009
|
1 min read
News
|
Feb. 7, 2007
|
1 min read
News
|
March 19, 2007
|
2 min read
New Effort Will Search for Potential Therapies Targeting the Most Common Mutation of Cystic Fibrosis
Press Release
|
Nov. 16, 2011
|
4 min read
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
News
|
Dec. 12, 2017
|
1 min read
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Press Release
|
Sept. 23, 2021
|
3 min read